International Institute for Musculoskeletal Health Education

The Clear Picture · Practical Guides

Heartburn Tablets and Your Bones

What the research really says about omeprazole, lansoprazole and the rest.

You may have read that acid reflux tablets weaken your bones. The research on this is more interesting, and a good deal more reassuring, than the headlines suggest. This guide explains what has actually been found, what it means for you, and what is worth raising at your next medication review.

The short answer

People who take these tablets long term do appear to have slightly more fractures than people who do not. But when researchers have measured bone density in the same people, they have mostly found no difference. The bones do not look thinner. That combination is unusual, and it tells us that the simplest explanation, that these tablets thin your bones, is probably wrong. The extra fractures are more likely to come from who takes these tablets (people who are, on average, less well and more likely to fall) than from what the tablets do to bone. This is not a reason to stop your tablets. It is a good reason to check, once a year, that you still need them.

Which tablets are we talking about?

This guide is about a group of medicines called proton pump inhibitors, usually shortened to PPIs. They reduce the amount of acid your stomach makes, and they are among the most widely prescribed medicines in the world. You may recognise one of these names on your box:

  • Omeprazole (often sold as Losec)
  • Lansoprazole (Zoton)
  • Esomeprazole (Nexium)
  • Pantoprazole (Protium)
  • Rabeprazole (Pariet)

They are prescribed for acid reflux and heartburn, for stomach and duodenal ulcers, for inflammation of the gullet, and to protect the stomach lining in people taking anti-inflammatory painkillers or certain other medicines. In some of those situations they are genuinely protective, they prevent serious bleeding, and stopping them would do considerably more harm than any effect on bone.

A second, older group of medicines does a gentler version of the same job: the histamine-2 blockers, such as famotidine, cimetidine and nizatidine. These will come up later, because comparing the two groups turns out to be the most useful thing anyone has done in this area.

Where did the worry come from?

In 2006 two large studies reported that people who had taken these tablets for a long time had more broken bones than people who had not. One found a 44% increase in hip fractures after a year or more of use. Others followed. A Canadian study found that seven or more years of use was linked to roughly double the risk of the kind of fracture associated with osteoporosis.

That was enough to generate headlines and a great many cautious review articles. The proposed explanation was straightforward and easy to remember: stomach acid helps you absorb calcium, these tablets reduce stomach acid, therefore they must reduce calcium absorption, therefore your bones must suffer.

It is a tidy chain of reasoning. Almost every link in it has since been tested, and most of them have broken.

What happened when researchers measured bone density?

This is the part that changed the picture, and it has never really reached the public.

The biggest study of its kind followed 161,806 women aged 50 to 79 in the United States for an average of nearly eight years. It did find some extra fractures in women taking these tablets. About 25% more fractures overall, and more spine and wrist fractures. But it found no extra hip fractures at all. And when the researchers scanned the women’s bones, they found that bone density in tablet-users and non-users was identical at the hip, the spine and across the whole body. Over the following years, the density of the tablet-users’ bones did not fall faster than anyone else’s.

Several other large studies have looked at the same question in the same way and reached the same conclusion: no meaningful difference in bone density, and no faster bone loss.

The puzzle in one sentence

More fractures, but no thinner bones. Whatever is going on, it is not ordinary bone loss, and that means the usual explanation you will find online is not the right one.

Does it make a difference whether you have been through the menopause, or take HRT?

This is a very good question, and it has been answered better than most questions in this area.

Oestrogen protects bone. When it falls at the menopause, bone is lost more quickly. So it would be reasonable to wonder whether these tablets only cause trouble in women who have already lost that protection, and whether HRT would therefore shield you.

In women past the menopause

The large American study mentioned above planned in advance to check exactly this. Roughly 1,600 of the women taking a stomach tablet were also taking HRT at the time. When the researchers compared women on HRT with women not on it, they found no difference in how the stomach tablets behaved. HRT neither made things worse nor protected against the effect.

In women going through the menopause

A different study followed around 2,000 American women through the menopause transition for about ten years, scanning their bones repeatedly. Some of them started a stomach tablet during that time; some started one of the older histamine-2 blockers; most took neither.

The researchers did something clever. They also looked at the women who started HRT, as a test of their own methods, because HRT is known to improve bone density, so if the study could not detect that, it could not be trusted to detect anything. It detected the HRT effect exactly as expected. And in the same women, using the same methods, it detected nothing whatsoever from the stomach tablets, at the spine, the hip or the femoral neck.

That is about as clean an answer as this kind of research produces. A method proven to work on the same data found no effect.

In younger people

A British study looked at more than 120,000 fractures in people aged between 4 and 29, an age group with no question of oestrogen loss at all. It found a link with fractures in the young adults, though not in the children. Whatever is happening, it is clearly not something that depends on the menopause.

So: is it the oestrogen, or is it the tablet? On the evidence, it appears to be neither, at least not in the way the question implies. Oestrogen status does not change the picture, and the tablets do not appear to be thinning bone. Something else is producing the extra fractures.

If it is not bone thinning, what is it?

There are three serious candidates, and they are not mutually exclusive.

1. Who takes these tablets

This is almost certainly the largest part of the answer, and it is the least discussed. In that study of 161,806 women, the ones taking a stomach tablet were, compared with everyone else:

  • More likely to be obese (44% against 29%)
  • Much less likely to have good physical function (16% against 38%)
  • Nearly three times as likely to rate their own health as fair or poor (23% against 8%)
  • Far more likely to have arthritis, heart disease, lung disease or diabetes
  • Three times as likely to be taking medicines that affect alertness and balance (27% against 9%)

That is a description of a group of people who are more likely to fall. And falling, not bone density, is what breaks most bones. Researchers adjust their figures to allow for these differences, but adjustment only removes the part you have measured. The rest stays in the result and looks like a drug effect.

2. Falls

Remarkably few studies in this area have actually counted falls. Given the picture above, this is a significant gap. A fracture needs both a fragile bone and an event that loads it. Most of the research has looked only at the first.

3. A possible effect on how bone hardens

There is one genuinely interesting laboratory finding. Bone is built in two stages: a soft protein scaffold is laid down first, and then mineral is deposited into it to make it hard. An enzyme called PHOSPHO1 is essential to that second stage.

Researchers in Brighton and Edinburgh found that every proton pump inhibitor they tested blocks this enzyme in the laboratory and slows the hardening of bone grown in culture. The older histamine-2 blockers do not do this at all.

If this turns out to matter in real people, and that is still an open question, because laboratory concentrations are not the same as the amounts that reach your bones, it would explain the puzzle neatly. Bone that contains the normal amount of mineral but has not hardened quite properly would show up as normal on a standard bone density scan, while still being slightly easier to break. In other words, the scan everyone has been using to look for the problem may be the wrong instrument for finding it.

What does this mean for you?

Please read this first. Nothing in this guide is a reason to stop a prescribed medicine. Stopping a proton pump inhibitor suddenly can cause a temporary surge of acid and a sharp return of symptoms, and in some people these tablets are preventing a dangerous stomach bleed. Any change should only be made after consulting your GP or pharmacist, and usually gradually.

With that said, here is a sensible way to think about it.

If this is you What is reasonable
You take a PPI short term, or now and then, for heartburn There is no evidence of any effect on bone at this level of use. Nothing to do.
You have been on a PPI for years without anyone reviewing it This is the common situation and the one worth acting on. Ask for a review, not because of your bones specifically, but because repeat prescriptions drift on by default.
You take a PPI to protect your stomach from anti-inflammatory painkillers or other medicines The protection is real and well established. The right question is whether you still need the painkiller, not whether you should drop the protection.
You have osteoporosis or have already broken a bone, and take a PPI Worth raising, but the evidence does not suggest the tablet is making your bones thinner. Focus on the things that are proven to help: strength and balance work, protein, calcium, vitamins D3 and K2, reviewing everything that increases your fall risk.
You take a PPI and are on HRT The research specifically looked at this. HRT does not appear to change the picture either way.

Five things worth doing

  • Ask whether you still need it. The single most useful action. Many people are on these tablets years after the reason has gone. Your GP or pharmacist can advise whether stepping down, or taking it only when symptoms appear, would suit you, and if so, how to do it gradually.
  • Do not focus on calcium as the answer. It is a reasonable thing to get enough of anyway, but in the large studies extra calcium did not reduce the fracture risk in tablet-users, another sign that calcium absorption is not the problem here.
  • Take falls seriously. Since falls are the most likely explanation for the extra fractures, this is where the real return is. Strength and balance training, a review of any medicines that make you drowsy or unsteady, eyesight and hearing checks, and sorting out trip hazards at home will do far more for you than worrying about your reflux tablet.
  • Keep up the loading. Bone responds to being worked. Progressive resistance training and impact exercise remain the most reliable non-drug ways of maintaining bone strength, whatever else you are taking.
  • If you are due a bone scan, have it on its merits. Take a scan because your fracture risk warrants one, not because you take omeprazole. On current evidence, a stomach tablet is not a reason to expect a poor result.

Questions worth asking at your next medical review

  • What was this tablet originally started for, and does that reason still apply?
  • Could I try a lower dose, or take it only when I have symptoms?
  • If I stop it, how should that be done, and what should I expect in the first couple of weeks?
  • Am I taking anything else that increases my risk of falling?
  • Given everything else about me, does my overall fracture risk warrant assessment?

The bottom line

Long-term users of acid reflux tablets do have a slightly higher fracture rate, but their bone density is not lower, and the effect does not depend on the menopause or on whether you take HRT. The most likely explanations are the general health of the people who take these tablets and their higher risk of falling, possibly with a small direct effect on how bone hardens that standard scans cannot see. This is a reason to review whether you still need the tablet, and a strong reason to work on your balance and strength. It is not a reason to stop a medicine that is doing an important job.

Where the figures in this guide come from

  1. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71. The 161,806-woman study, including the HRT comparison and the bone density scans.
  2. Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2015;30(2):232–9. The study following women through the menopause, using HRT to check its own methods.
  3. Hansen KE, Nieves JW, Nudurupati S, Metz DC, Perez MC. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019;156(4):926–34.e6. The trial that measured calcium absorption directly and found no effect.
  4. Staines KA, Myers K, Little K, Ralston SH, Farquharson C. Proton pump inhibitors inhibit PHOSPHO1 activity and matrix mineralisation in vitro. Calcif Tissue Int. 2021;109(6):696–705. The laboratory work on bone hardening.
  5. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501–7. The study in people aged 4 to 29.
  6. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26. The Canadian long-duration study (1).
  7. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904. The Canadian long-duration study (2).
  8. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53. One of the two original 2006 reports.

This guide is written by the Education Directorate of IIMHE for general information and is not a substitute for advice about your own treatment. Do not start, stop or change any prescribed medicine on the basis of what you have read here. Speak to your GP or pharmacist, who knows why your tablet was started and what else you are taking. IIMHE · The Clear Picture · Practical Guides.

NEXT WEBINAR

2nd February 2026 @ 20:00 GMT

Nutrition and musculoskeletal health

Given by: Dr Kimberley Zambito, Orthopaedic Consultant 

Hosted by: Dr Nick Birch

Throughout 2026 and beyond,  IIMHE (the International Institute of Musculoskeletal Health Education), in partnership with OsteoscanUK, will host a series of engaging educational webinars, open to anyone interested in bone and musculoskeletal health.